Amgen (AMGN) Commits $300M to Expand Puerto Rico Manufacturing

TLDR

• Amgen has unveiled an additional $300 million investment to expand its biologics production facility in Juncos, Puerto Rico.
• The site supplies medications to over 60 countries and will receive expanded production capacity.
• This move is on top of more than $650 million Amgen already announced for Puerto Rico over the past 12 months.
• Amgen’s total U.S. manufacturing commitments over the last year surpass $3.65 billion, spanning Puerto Rico, Ohio, California, and North Carolina.
• This investment comes as pharmaceutical manufacturers respond to President Trump’s executive order that threatens 100% tariffs on imported brand-name medicines.

---

(SeaPRwire) –   Shares of Amgen (AMGN) dropped 1.54% on Monday as the company announced a new $300 million investment to expand its biologics manufacturing facility in Juncos, Puerto Rico.

Amgen Inc., ticker AMGN

The expansion is designed to increase production capacity and advance next-generation manufacturing technologies at the site, which has been operational since 1992.

The Juncos facility currently distributes biologic medicines to over 60 countries. The investment will reinforce existing manufacturing roles at the site and create hundreds of construction positions.

CEO Robert Bradway stated the expansion reflects Amgen’s “ongoing commitment to American manufacturing” and is built to protect domestic supply chains and patient access to medications.

Puerto Rico Governor Jenniffer González Colón welcomed the announcement, noting the investment confirms that policies supporting the island’s biopharmaceutical sector are delivering results.

This $300 million adds to the $650 million Amgen had already earmarked for Puerto Rico over the past year, a prior commitment that was projected to create roughly 750 jobs.

Broader U.S. Manufacturing Expansion Effort

This latest commitment is part of a far larger domestic investment strategy. Over the past year, Amgen has announced $900 million in investments for Ohio, $600 million for a science and innovation hub in California, and more than $1.5 billion for projects in North Carolina.

Combined with the new Puerto Rico announcement, Amgen’s recent U.S. manufacturing commitments add up to more than $3.65 billion in total.

Since the 2017 Tax Cuts and Jobs Act was passed, Amgen reports it has invested over $40 billion in manufacturing and research and development work.

Underlying Tariff Pressures

This investment arrives as global drugmakers face growing pressure from the Trump administration related to pharmaceutical imports.

President Trump signed an executive order in April that imposes 100% tariffs on branded pharmaceuticals imported into the U.S., unless manufacturers agree to government drug-pricing deals or make commitments to domestic production.

Amgen’s expanded U.S. operational footprint positions the company to navigate these pressures, though the company framed the Puerto Rico move as part of its long-term supply chain strategy.

Puerto Rico, a U.S. territory, has served as a pharmaceutical manufacturing hub for more than 60 years and hosts facilities for a number of major drug companies.

The Juncos site has been part of Amgen’s operational network since 1992 and plays a core role in the company’s global biologics supply chain.

Amgen has not shared a specific timeline for the completion of the latest Puerto Rico expansion project.